Terms: = Germ cell tumor AND HIST1H3B, H3_1, P68431, H3FJ, H3/j, H3FF, H3/f, H3_f, H3FK, H3F1K, H3/k, H3FH, H3/h, H3FI, H3/i, H3FD, H3/d, H3FB, H3/b, H3FC, H3/c, H3FL, H3/l, H3FA, H3/A, ENSG00000124693, 8358
96 results:
1. H2A.Z histone variants facilitate HDACi-dependent removal of H3.3K27M mutant protein in pediatric high-grade glioma cells.
Leszczynska KB; Freitas-Huhtamäki A; Jayaprakash C; Dzwigonska M; Vitorino FNL; Horth C; Wojnicki K; Gielniewski B; Szadkowska P; Kaza B; Nazarian J; Ciolkowski MK; Trubicka J; Grajkowska W; Garcia BA; Majewski J; Kaminska B; Mieczkowski J
Cell Rep; 2024 Feb; 43(2):113707. PubMed ID: 38306270
[TBL] [Abstract] [Full Text] [Related]
2. Clinicohistoradiological and surgical outcome in diffuse midline glioma.
Kumar Suman A; Bhattacharjee S; Uppin MS; Fathima ST
Childs Nerv Syst; 2024 Jan; 40(1):65-71. PubMed ID: 37644138
[TBL] [Abstract] [Full Text] [Related]
3. Dynamic susceptibility contrast perfusion-weighted and diffusion-weighted magnetic resonance imaging findings in pilocytic astrocytoma and H3.3 and H3.1 variant diffuse midline glioma, H3K27-altered.
Kurokawa R; Kurokawa M; Baba A; Kim J; Srinivasan A; Moritani T
PLoS One; 2023; 18(7):e0288412. PubMed ID: 37450487
[TBL] [Abstract] [Full Text] [Related]
4. Targeting B7-H3-A Novel Strategy for the Design of Anticancer Agents for Extracranial Pediatric Solid tumors Treatment.
Rasic P; Jeremic M; Jeremic R; Dusanovic Pjevic M; Rasic M; Djuricic SM; Milickovic M; Vukadin M; Mijovic T; Savic D
Molecules; 2023 Apr; 28(8):. PubMed ID: 37110590
[TBL] [Abstract] [Full Text] [Related]
5. Imaging features of localized IDH wild-type histologically diffuse astrocytomas: a single-institution case series.
Kibe Y; Motomura K; Ohka F; Aoki K; Shimizu H; Yamaguchi J; Nishikawa T; Saito R
Sci Rep; 2023 Jan; 13(1):23. PubMed ID: 36646712
[TBL] [Abstract] [Full Text] [Related]
6. Advances and Clinical Trials Update in the Treatment of Diffuse Intrinsic Pontine Gliomas.
Dalle Ore C; Coleman C; Gupta N; Mueller S
Pediatr Neurosurg; 2023; 58(5):259-266. PubMed ID: 36642062
[TBL] [Abstract] [Full Text] [Related]
7. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
Day CA; Hinchcliffe EH; Robinson JP
Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
[TBL] [Abstract] [Full Text] [Related]
8. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
[TBL] [Abstract] [Full Text] [Related]
9. A pediatric bithalamic high grade glioma with concomitant H3K27M and EGFR mutations.
Kara B; Danyeli AE; Öztürk M; Ertan K; Köksal Y
Turk J Pediatr; 2022; 64(4):754-758. PubMed ID: 36082650
[TBL] [Abstract] [Full Text] [Related]
10. Radiomic Features Based on MRI Predict Progression-Free Survival in Pediatric Diffuse Midline Glioma/Diffuse Intrinsic Pontine Glioma.
Wagner MW; Namdar K; Napoleone M; Hainc N; Amirabadi A; Fonseca A; Laughlin S; Shroff MM; Bouffet E; Hawkins C; Khalvati F; Bartels U; Ertl-Wagner BB
Can Assoc Radiol J; 2023 Feb; 74(1):119-126. PubMed ID: 35768942
[No Abstract] [Full Text] [Related]
11. The prognostic significance of hist1h3b/C and H3F3A K27M mutations in diffuse midline gliomas is influenced by patient age.
Vuong HG; Ngo TNM; Le HT; Dunn IF
J Neurooncol; 2022 Jul; 158(3):405-412. PubMed ID: 35606633
[TBL] [Abstract] [Full Text] [Related]
12. Diffuse Midline Gliomas With Histone H3 K27M Mutation in Adults and Children: A Retrospective Series of 164 Cases.
Zheng L; Gong J; Yu T; Zou Y; Zhang M; Nie L; Chen X; Yue Q; Liu Y; Mao Q; Zhou Q; Chen N
Am J Surg Pathol; 2022 Jun; 46(6):863-871. PubMed ID: 35416795
[TBL] [Abstract] [Full Text] [Related]
13. [Diffuse midline gliomas with H3K27 alteration in children: a clinicopathological analysis of forty-one cases].
Li J; Ma YY; Feng J; Zhao D; Ding F; Tian L; Chen R; Zhao R
Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):319-325. PubMed ID: 35359043
[No Abstract] [Full Text] [Related]
14. [Diffuse midline glioma].
Saito R
No Shinkei Geka; 2022 Jan; 50(1):29-38. PubMed ID: 35169084
[TBL] [Abstract] [Full Text] [Related]
15. Magnetic Resonance Imaging Characteristics of Molecular Subgroups in Pediatric H3 K27M Mutant Diffuse Midline Glioma.
Hohm A; Karremann M; Gielen GH; Pietsch T; Warmuth-Metz M; Vandergrift LA; Bison B; Stock A; Hoffmann M; Pham M; Kramm CM; Nowak J
Clin Neuroradiol; 2022 Mar; 32(1):249-258. PubMed ID: 34919158
[TBL] [Abstract] [Full Text] [Related]
16. Targeted therapy with anlotinib for a H3K27M mutation diffuse midline glioma patient with PDGFR-α mutation: a case report.
Wang Q; Niu W; Pan H
Acta Neurochir (Wien); 2022 Aug; 164(8):2063-2066. PubMed ID: 34812950
[TBL] [Abstract] [Full Text] [Related]
17. H3K27M-mutant diffuse midline gliomas should be further molecularly stratified: an integrated analysis of 669 patients.
Vuong HG; Le HT; Ngo TNM; Fung KM; Battiste JD; McNall-Knapp R; Dunn IF
J Neurooncol; 2021 Dec; 155(3):225-234. PubMed ID: 34796414
[TBL] [Abstract] [Full Text] [Related]
18. Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies.
Findlay IJ; De Iuliis GN; Duchatel RJ; Jackson ER; Vitanza NA; Cain JE; Waszak SM; Dun MD
Oncogene; 2022 Jan; 41(4):461-475. PubMed ID: 34759345
[TBL] [Abstract] [Full Text] [Related]
19. Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
Makino Y; Arakawa Y; Yoshioka E; Shofuda T; Minamiguchi S; Kawauchi T; Tanji M; Kanematsu D; Nonaka M; Okita Y; Kodama Y; Mano M; Hirose T; Mineharu Y; Miyamoto S; Kanemura Y
BMC Cancer; 2021 Sep; 21(1):1025. PubMed ID: 34525976
[TBL] [Abstract] [Full Text] [Related]
20. Characteristics of patients ≥10 years of age with diffuse intrinsic pontine glioma: a report from the International DIPG/DMG Registry.
Erker C; Lane A; Chaney B; Leary S; Minturn JE; Bartels U; Packer RJ; Dorris K; Gottardo NG; Warren KE; Broniscer A; Kieran MW; Zhu X; White P; Dexheimer PJ; Black K; Asher A; DeWire M; Hansford JR; Gururangan S; Nazarian J; Ziegler DS; Sandler E; Bartlett A; Goldman S; Shih CS; Hassall T; Dholaria H; Bandopadhayay P; Samson Y; Monje M; Fisher PG; Dodgshun A; Parkin S; Chintagumpala M; Tsui K; Gass D; Larouche V; Broxson E; Garcia Lombardi M; Wang SS; Ma J; Hawkins C; Hamideh D; Wagner L; Koschmann C; Fuller C; Drissi R; Jones BV; Leach J; Fouladi M
Neuro Oncol; 2022 Jan; 24(1):141-152. PubMed ID: 34114629
[TBL] [Abstract] [Full Text] [Related]
[Next]
